NCT01179997

Brief Summary

The aim of this study was to compare the response to cardiac resynchronization therapy when the interventricular pacing interval was optimized by Tissue Doppler Imaging (TDI) to response when it was optimized following QRS width criteria.

Trial Health

80
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
156

participants targeted

Target at P25-P50 for phase_3 heart-failure

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 5, 2010

Completed
6 days until next milestone

First Posted

Study publicly available on registry

August 11, 2010

Completed
Last Updated

February 27, 2014

Status Verified

May 1, 2010

First QC Date

August 5, 2010

Last Update Submit

February 26, 2014

Conditions

Outcome Measures

Primary Outcomes (1)

  • 6-month echocardiographic response

    Reduction of the end-systolic volume (measured in mililiters according to transthoracic echocardiography) of \>10% as compared to the baseline value.

Secondary Outcomes (1)

  • 6-month clinical response

Study Arms (2)

Tissue Doppler Imaging (TDI) optimization

ACTIVE COMPARATOR

Interventricular pacing delay optimized according to Tissue-Doppler echocardiography

Device: Interventricular pacing delay optimization by using Tissue Doppler-derived displacement curves

Electrocardiographic optimization

ACTIVE COMPARATOR

Interventricular pacing delay optimized according to QRS width observation in the 12-lead surface electrocardiogram

Device: Electrocardiographic optimization of the interventricular pacing delay according to QRS width

Interventions

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Patients submitted to de novo implant due to conventional cardiac resynchronization therapy indications.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hospital Clinic Universitari

Barcelona, Catalonia, Spain

Location

MeSH Terms

Conditions

Heart Failure

Condition Hierarchy (Ancestors)

Heart DiseasesCardiovascular Diseases

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD PhD

Study Record Dates

First Submitted

August 5, 2010

First Posted

August 11, 2010

Last Updated

February 27, 2014

Record last verified: 2010-05

Locations